SG11201703323PA - TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt - Google Patents

TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Info

Publication number
SG11201703323PA
SG11201703323PA SG11201703323PA SG11201703323PA SG11201703323PA SG 11201703323P A SG11201703323P A SG 11201703323PA SG 11201703323P A SG11201703323P A SG 11201703323PA SG 11201703323P A SG11201703323P A SG 11201703323PA SG 11201703323P A SG11201703323P A SG 11201703323PA
Authority
SG
Singapore
Prior art keywords
roryt
modulators
trifluoromethyl alcohols
trifluoromethyl
alcohols
Prior art date
Application number
SG11201703323PA
Other languages
English (en)
Inventor
Hariharan Venkatesan
Virginia Tanis
Olaf Kinzel
Christian Gege
Christoph Steeneck
Gerald Kleymann
Thomas Hoffmann
Steven Goldberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703323P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201703323PA publication Critical patent/SG11201703323PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201703323PA 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt SG11201703323PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30
PCT/US2015/058193 WO2016069974A1 (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Publications (1)

Publication Number Publication Date
SG11201703323PA true SG11201703323PA (en) 2017-05-30

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703323PA SG11201703323PA (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
SG10201805355YA SG10201805355YA (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201805355YA SG10201805355YA (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Country Status (40)

Country Link
US (2) US9850236B2 (enrdf_load_stackoverflow)
EP (2) EP3212643B1 (enrdf_load_stackoverflow)
JP (3) JP6998204B2 (enrdf_load_stackoverflow)
KR (2) KR20170127580A (enrdf_load_stackoverflow)
CN (3) CN107108599A (enrdf_load_stackoverflow)
AR (2) AR102480A1 (enrdf_load_stackoverflow)
AU (2) AU2015339087B2 (enrdf_load_stackoverflow)
BR (2) BR122017023050A2 (enrdf_load_stackoverflow)
CA (1) CA2965512C (enrdf_load_stackoverflow)
CL (3) CL2017001042A1 (enrdf_load_stackoverflow)
CO (1) CO2017005014A2 (enrdf_load_stackoverflow)
CR (2) CR20170542A (enrdf_load_stackoverflow)
CY (1) CY1121716T1 (enrdf_load_stackoverflow)
DK (1) DK3212643T3 (enrdf_load_stackoverflow)
EA (2) EA033699B1 (enrdf_load_stackoverflow)
EC (1) ECSP17033054A (enrdf_load_stackoverflow)
ES (2) ES2858503T3 (enrdf_load_stackoverflow)
GT (1) GT201700090A (enrdf_load_stackoverflow)
HR (1) HRP20190900T1 (enrdf_load_stackoverflow)
HU (1) HUE043624T2 (enrdf_load_stackoverflow)
IL (2) IL251865A0 (enrdf_load_stackoverflow)
JO (2) JOP20200117A1 (enrdf_load_stackoverflow)
LT (1) LT3212643T (enrdf_load_stackoverflow)
MA (1) MA40873B1 (enrdf_load_stackoverflow)
ME (1) ME03426B (enrdf_load_stackoverflow)
MX (2) MX367912B (enrdf_load_stackoverflow)
PE (2) PE20180250A1 (enrdf_load_stackoverflow)
PH (2) PH12017500800B1 (enrdf_load_stackoverflow)
PL (1) PL3212643T3 (enrdf_load_stackoverflow)
PT (1) PT3212643T (enrdf_load_stackoverflow)
RS (1) RS58613B1 (enrdf_load_stackoverflow)
SG (2) SG11201703323PA (enrdf_load_stackoverflow)
SI (1) SI3212643T1 (enrdf_load_stackoverflow)
SM (1) SMT201900290T1 (enrdf_load_stackoverflow)
SV (1) SV2017005429A (enrdf_load_stackoverflow)
TR (1) TR201907763T4 (enrdf_load_stackoverflow)
TW (2) TWI667230B (enrdf_load_stackoverflow)
UY (2) UY36377A (enrdf_load_stackoverflow)
WO (1) WO2016069974A1 (enrdf_load_stackoverflow)
ZA (3) ZA201703679B (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
CN112118841A (zh) 2018-03-12 2020-12-22 爱思凯利尔生物科学私人有限责任公司 螺环ROR-γ调节剂
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
WO2019243999A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
EP3807251B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV Phenyl and pyridinyl substituted imidazoles as modulators of roryt
JP2021529161A (ja) 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレーターとしてのピリジニルピラゾール
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP1125932A3 (en) 1994-07-27 2001-08-29 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
CN100540538C (zh) 2001-04-16 2009-09-16 田边三菱制药株式会社 高传导率钙-活化k通道开启剂
DE60211348T2 (de) 2001-08-13 2007-02-08 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
AR045651A1 (es) * 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2583557B1 (de) 2008-07-17 2016-01-13 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
US8377962B2 (en) * 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
PT3002008T (pt) 2010-03-11 2018-12-24 Univ New York Compostos de amido como moduladores roryt e suas utilizações
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
KR101958699B1 (ko) 2010-12-28 2019-03-15 라이온 가부시키가이샤 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2014002810A (es) 2011-09-09 2014-09-08 Univ New York Compuestos amido como moduladores del receptor nuclear huérfanoyt y usos de los mismos.
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
PE20150229A1 (es) * 2012-05-31 2015-03-02 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano rory
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
PE20151203A1 (es) * 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
WO2014093191A1 (en) * 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9663469B2 (en) 2013-09-09 2017-05-30 Bristol-Myers Squibb Company RORγ modulators
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
WO2015042212A1 (en) 2013-09-20 2015-03-26 Bristol-Myers Squibb Company RORγ MODULATORS
AU2013403336A1 (en) * 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORyt
BR112016008215A2 (pt) * 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9738600B2 (en) 2013-12-05 2017-08-22 Lead Pharma Cel Models Ip B.V. ROR gamma (RORγ) modulators
WO2015103507A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Cyclohexyl sulfone rorϒ modulators
WO2015103510A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Heterocyclic sulfone as ror-gamma modulators
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
WO2015103509A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
EP3122721A4 (en) 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
RS59752B1 (sr) 2014-10-30 2020-02-28 Janssen Pharmaceutica Nv Amidno supstituisani tiazoli kao modulatori rorgamat
HRP20190174T1 (hr) 2014-10-30 2019-03-22 Janssen Pharmaceutica Nv Tiazoli kao modulatori roryt

Also Published As

Publication number Publication date
EP3354651B1 (en) 2021-01-06
US9850236B2 (en) 2017-12-26
TW201927759A (zh) 2019-07-16
CO2017005014A2 (es) 2017-08-31
ZA201805860B (en) 2019-11-27
ES2724556T3 (es) 2019-09-12
CA2965512C (en) 2020-03-10
PH12017500800A1 (en) 2017-10-02
AR102480A1 (es) 2017-03-01
EP3212643A1 (en) 2017-09-06
RS58613B1 (sr) 2019-05-31
TWI667230B (zh) 2019-08-01
JP2020180129A (ja) 2020-11-05
JP2019059728A (ja) 2019-04-18
ECSP17033054A (es) 2018-01-31
JO3571B1 (ar) 2020-07-05
SV2017005429A (es) 2017-10-17
MX2017005689A (es) 2018-02-19
MA40873B1 (fr) 2019-07-31
JP6998204B2 (ja) 2022-02-04
PL3212643T3 (pl) 2019-08-30
GT201700090A (es) 2019-08-08
SG10201805355YA (en) 2018-07-30
EA201790942A1 (ru) 2017-09-29
TR201907763T4 (tr) 2019-06-21
IL255648B (en) 2020-06-30
UY37517A (es) 2018-01-31
PT3212643T (pt) 2019-06-17
TW201629027A (zh) 2016-08-16
AR110155A2 (es) 2019-02-27
CL2019001514A1 (es) 2019-10-04
AU2015339087B2 (en) 2020-01-23
PH12017502105A1 (en) 2019-11-25
SI3212643T1 (sl) 2019-04-30
KR20170078750A (ko) 2017-07-07
MA40873A (fr) 2017-09-05
HUE043624T2 (hu) 2019-08-28
EA033699B1 (ru) 2019-11-18
BR112017008816A2 (pt) 2017-12-19
EP3354651A1 (en) 2018-08-01
MX367912B (es) 2019-09-11
JOP20200117A1 (ar) 2017-06-16
WO2016069974A1 (en) 2016-05-06
IL255648A (en) 2018-01-31
ES2858503T3 (es) 2021-09-30
BR122017023050A2 (pt) 2019-09-10
CL2018000436A1 (es) 2018-07-06
UY36377A (es) 2016-04-29
AU2015339087A1 (en) 2017-05-11
US20160122336A1 (en) 2016-05-05
CN112979630A (zh) 2021-06-18
CR20170166A (es) 2017-08-22
EA201891562A2 (ru) 2018-12-28
EP3212643B1 (en) 2019-03-20
TWI705057B (zh) 2020-09-21
US20170327492A1 (en) 2017-11-16
CL2017001042A1 (es) 2017-12-01
CR20170542A (es) 2018-02-20
PE20180250A1 (es) 2018-02-02
EA035998B1 (ru) 2020-09-10
AU2019200228A1 (en) 2019-01-31
IL251865A0 (en) 2017-06-29
HK1258212A1 (en) 2019-11-08
JP2018500287A (ja) 2018-01-11
ZA201703679B (en) 2019-06-26
PE20171649A1 (es) 2017-11-13
PH12017500800B1 (en) 2017-10-02
ME03426B (me) 2020-01-20
US10150762B2 (en) 2018-12-11
JP6623270B2 (ja) 2019-12-18
LT3212643T (lt) 2019-06-10
KR20170127580A (ko) 2017-11-21
SMT201900290T1 (it) 2019-07-11
EA201891562A3 (ru) 2019-04-30
ZA201805861B (en) 2019-11-27
MX369567B (es) 2019-11-12
CN107827841A (zh) 2018-03-23
CY1121716T1 (el) 2020-07-31
AU2019200228B2 (en) 2020-04-16
CA2965512A1 (en) 2016-05-06
CN107108599A (zh) 2017-08-29
DK3212643T3 (da) 2019-05-13
HRP20190900T1 (hr) 2019-07-12

Similar Documents

Publication Publication Date Title
IL259421B (en) ror - gamma modulators
EP3140722A4 (en) Characterizing states of subject
ZA201805860B (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
SG11201704080YA (en) Optical modulator
LT3212641T (lt) Tiazolai, kaip roryt moduliatoriai
SI3524234T1 (sl) Trdne oblike sofosbuvira
SG11201606371TA (en) Cosmetic vessel
IL246979A0 (en) Crystalline forms of sofosbuvir
SG11201610243YA (en) Treatment of severe hypertriglyceridemia
GB201414885D0 (en) Optically controlled devices
GB201415598D0 (en) Elavated Itercranial Pressure Treatment
IL249130B (en) Preparation of piperidine-4-carbothioamide
IL247234A0 (en) Caspase-6 modulators
SG11201607445QA (en) Methods of modulating wars2
GB201420904D0 (en) Liquid filter - reservoir
IL249332A0 (en) Crystalline forms of sofosbuvir
TWM489666U (en) Structure of goggles
GB201400215D0 (en) Modulators
IL234315A0 (en) best wishes
GB201405142D0 (en) Theory of restoration
AU358519S (en) Cosmetic device
TWM489399U (en) Improved structure of USB transmission device
GB201405154D0 (en) Theory of hairdressing
TWM489754U (en) Uniform-heating device of mold
GB201407133D0 (en) Care Dome - Indoors